Abstract 1829P
Background
To investigate the nutritional status of hospitalized patients with common malignant tumor in a cancer hospital of Southwest China.
Methods
From April 2017 to May 2021, we enrolled 891 patients with cancer hospitalized for treatment in Chongqing university Cancer Hospital. These patients were diagnosed with one of the following 16 different types of malignant tumors: lung cancer, gastric cancer, liver cancer, colorectal cancer, breast cancer, esophageal cancer, cervical cancer, endometrial cancer, nasopharyngeal carcinoma, malignant lymphoma, leukemia, pancreatic cancer, ovarian cancer, prostate cancer, bladder cancer and brain tumor. Patient-generated subjective global assessment (PG-SGA), anthropometric measurements, and laboratory examination were used to evaluate the nutritional risk or nutritional status.Cancer pain status were assessed with the Numerical Rating Scale (NRS). We also investigated the nutritional therapy of these cancer patients.
Results
According to the PG-SGA score, 48.7% (434/891) of the cancer patients were severe malnutrition (PG-SGA≥9), 31.2% (312/891) were moderate malnutrition (8≥PG-SGA≥4), 14.7% (131/891) were mild malnutrition (PG-SGA 2∼3), and only 5.4% (48/891) patients were no malnutrition (PG-SGA 0∼1). The rate of malnutrition for gastrointestinal cancer patients is higher than Nongastrointestinal cancer patients (67.3% vs. 44.6%, χ2=31.48, P <0.001). Multiple linear regression analysis, PG-SGA scores and body mass index (P<0.001), serum total protein(P<0.001), hemoglobin serum(P<0.001), albumin (P<0.001), prealbumin (P<0.001), calf circumference (left side, P=0.001) were correlated. Age(≥65 years), albumin(<40g/L), prealbumin (<150mg/L) and cancer pain (NRS≥4) are the risk factors of severe malnutrition. However, only 26.8% (200/746) of all the moderately and severely malnourished patients received nutritional therapy.
Conclusions
94.6% of the common malignant tumor patients enrolled in the present study were malnutrition. Nutritional therapy of malignant tumor patients with malnutrition is very low.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1874P - Time to vomiting after chemotherapy in association with number of emetic risk factors among breast cancer patients receiving highly emetogenic chemotherapy
Presenter: Winnie Yeo
Session: Poster session 12
1875P - Real-world evidence of ribociclib induced liver toxicity in patients with breast cancer: A multi-center experience
Presenter: Onur Bas
Session: Poster session 12
1877P - Adverse effects (AEs) of trastuzumab deruxtecan (T-DXd) in solid tumours: A meta-analysis
Presenter: Neha Pathak
Session: Poster session 12
1878P - Efficacy of surgical gloves (SG) as compression therapy to prevent oxaliplatin-induced peripheral neuropathy (PN): The ELEGANT trial
Presenter: Aurélia JOUREAU-CHABERT
Session: Poster session 12
1879P - Effectiveness of intravenous fosnetupitant & palonosetron for cinv prophylaxis in patients receiving highly emetogenic chemotherapy regimens: Subgroup analysis from a phase IV Indian study
Presenter: Arun Kumar Verma
Session: Poster session 12
1880P - Antiemetic prophylaxis during chemoradiation: Sub-study of the GAND-emesis trial identifying dosimetric predictors for vomiting
Presenter: Anika Johannsdottir
Session: Poster session 12
1881P - Enhancing chemotherapy-induced nausea and vomiting management: Insights into guideline adherence and patient outcomes
Presenter: Suresh Attili
Session: Poster session 12
1882P - Awareness of chemotherapy induced nausea and vomiting and adherence to guidelines: A multinational and multicenter survey
Presenter: Ricardo Caponero
Session: Poster session 12
1883P - Impact of geriatrician-implemented Interventions on chemotherapy (CT) delivery in vulnerable elderly patients with early or advanced solid tumors: The GIVE trial
Presenter: Emanuela Risi
Session: Poster session 12
1884P - Development and validation of a prediction tool for severe treatment-related toxicities in older cancer patients on systemic treatment (TR-TRM)
Presenter: Wendy Chan
Session: Poster session 12